Multiple sclerosis (Houndmills, Basingstoke, England) · 2024
Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.
Montalban et al.
PhotobiomodulationClinical trial
- Journal
- Multiple sclerosis (Houndmills, Basingstoke, England)
- Year
- 2024
- Publication type
- Randomized Controlled Trial|Clinical Trial, Phase II|Journal Article